DENTSPLY SIRONA director receives RSU stock grant

Gladden Brian T reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Gladden Brian T reported acquisition or exercise transactions in this Form 4 filing.

DENTSPLY SIRONA Inc. director Brian T. Gladden received an equity grant tied to the company’s common stock. The award covers 22,822 shares at a price of $0.00 per share as a compensation grant rather than a market purchase.

The footnotes state this grant consists entirely of Restricted Stock Units (RSUs) that vest in full one year from the grant date, meaning all restrictions lapse at that time if vesting conditions are met. Following this grant, Gladden’s direct holdings increase to 51,863.522 shares of common stock.

Insider Trade Summary

Grant/Award: 22,822 shares

Grant/Award 1 txn

Insider Gladden Brian T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	22,822	$0.00	$0.00

Holdings After Transaction: Common Stock — 51,863.522 shares (Direct)

Footnotes (1)

1. F1. This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.

Key Figures

RSU grant size: 22,822 shares Grant price per share: $0.00 per share Post-transaction holdings: 51,863.522 shares +2 more

5 metrics

RSU grant size 22,822 shares Equity grant on 2026-06-03 coded as grant/award acquisition

Grant price per share $0.00 per share Compensation-related RSU grant, not an open-market purchase

Post-transaction holdings 51,863.522 shares Total common stock directly owned after the RSU grant

Vesting period One year RSUs vest in full one year from the grant date

Transaction type Grant, award, or other acquisition Transaction code A for non-derivative common stock

Key Terms

Restricted Stock Units (RSUs), Common Stock, Grant, award, or other acquisition

3 terms

Restricted Stock Units (RSUs) financial

"This grant consists entirely of Restricted Stock Units (RSUs) that vest in full..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Common Stock financial

"security_title: Common Stock in the non-derivative transaction record"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DENTSPLY SIRONA (XRAY) report for Brian T. Gladden?

DENTSPLY SIRONA reported that director Brian T. Gladden received an equity grant of 22,822 shares tied to common stock. The award is coded as a grant or award acquisition, with a price of $0.00 per share as compensation rather than an open-market trade.

How many DENTSPLY SIRONA (XRAY) shares were granted to Brian T. Gladden?

Brian T. Gladden was granted 22,822 shares related to DENTSPLY SIRONA common stock. These are structured as Restricted Stock Units that vest in full one year from the grant date, increasing his direct beneficial ownership when they vest, assuming all vesting conditions are satisfied.

What are the vesting terms of Brian T. Gladden’s RSU grant at DENTSPLY SIRONA (XRAY)?

The RSU grant vests in full one year from the date of grant, when all restrictions lapse. Until vesting, the units are subject to forfeiture conditions. After vesting, the RSUs convert into common shares in line with the grant’s terms described in the footnote.

What is Brian T. Gladden’s DENTSPLY SIRONA (XRAY) shareholding after this Form 4 transaction?

After the reported grant, Brian T. Gladden beneficially owns 51,863.522 DENTSPLY SIRONA common shares directly. This total reflects his position following the acquisition of 22,822 RSU-based shares recorded in the filing, as shown in the post-transaction ownership figure.

Was Brian T. Gladden’s DENTSPLY SIRONA (XRAY) grant a market purchase or a compensation award?

The transaction is a compensation award, not a market purchase. It is coded as a grant, award, or other acquisition with a transaction price of $0.00 per share, and consists entirely of Restricted Stock Units that vest after one year, according to the footnote.

Does the DENTSPLY SIRONA (XRAY) Form 4 show any stock sales by Brian T. Gladden?

The Form 4 excerpt shows only an acquisition transaction for Brian T. Gladden, specifically a grant of 22,822 RSU-based shares. The transaction summary lists one acquisition and no sales, gifts, tax withholdings, or derivative exercises in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 05:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gladden Brian T

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NORTH CAROLINA 28277

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		22,822(1)	A	$0	51,863.522	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Brian T. Gladden	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)